Viscoelastic hemostasis assays in septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians.
Blood Coagul Fibrinolysis
; 32(3): 225-228, 2021 Apr 01.
Article
in English
| MEDLINE | ID: covidwho-1028646
ABSTRACT
Coronavirus disease 2019 (COVID-19)-associated coagulopathy is unusual, poorly defined and is linked with significant hypercoagulability and microthrombotic and macrothrombotic complications leading to worse outcomes and higher mortality. Conventional coagulation assays do not always actively reflect these derangements and might fail to detect this coagulopathy. Viscoelastic hemostatic assays (VHA) provide a possible tool that adds to conventional coagulation assays in identifying this hypercoagulable state. VHA has been mostly used in surgery and trauma but it's still not well defined in sepsis patients with lack of large randomized trials. Few studies described VHA findings in patients with COVID-19 showing significant hypercoagulability and fibrinolysis shutdown. Clinicians taking care of these patients might have little experience interpreting VHA results. By reviewing the available literature on the use of VHA in sepsis, and the current knowledge on COVID-19-associated coagulopathy we provide clinicians with a practical guide on VHA utilization in patients with COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombelastography
/
Blood Coagulation Disorders
/
COVID-19
/
Hemostasis
Type of study:
Diagnostic study
/
Experimental Studies
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Blood Coagul Fibrinolysis
Journal subject:
Vascular Diseases
/
Hematology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS